source
- Sofinnova Partners raises €725 million for second crossover fund targeting late-stage European biotech firmsSofinnova Partners announced the closing of its second crossover fund with €725 million ($815 million) in commitments. The fund is designed to fill the financing gap for late-stage European biopha…
- Tandem Diabetes Care gets FDA clearance for tubeless insulin delivery system with up to 7-day wearTandem Diabetes Care announced that the FDA has cleared its Tandem Mobi system as a tubeless automated insulin delivery device. The clearance allows the device to be worn for up to seven days witho…